Evidence map›Paper›PMID 33838681›Full record

ArticleJournal of experimental & clinical cancer research : CR2021

NLRP7 deubiquitination by USP10 promotes tumor progression and tumor-associated macrophage polarization in colorectal cancer.

Bing Li, Zhi-Peng Qi, Dong-Li He, Zhang-Han Chen, Jing-Yi Liu, Meng-Wai Wong, Jia-Wei Zhang, En-Pan Xu, Qiang Shi, Shi-Lun Cai and 4 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers.

0numbers the graph read from it
0cells of the map it votes in
67citing papers in PubMed
5.6field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

67 citing papers in PubMed, 95 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Review
  5. Review
  6. Article
  7. TEITbase: a database for transposable element (TE)-initiated transcripts in human cancers.Database : the journal of biological databases and curation · 2026
    Article
  8. Article
  9. USP10-mediated deubiquitination and activation ofActa pharmaceutica Sinica. B · 2026
    Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

7 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 1 institution in 1 country.

Bing Li *Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Zhi-Peng Qi *Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Dong-Li He *Endoscopy Center, Xuhui Hospital, Zhongshan Hospital of Fudan University, Shanghai, 20031, People's Republic of China.
Zhang-Han Chen *Endoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Jing-Yi LiuEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Meng-Wai WongEndoscopy Center, Xuhui Hospital, Zhongshan Hospital of Fudan University, Shanghai, 20031, People's Republic of China.
Jia-Wei ZhangDepartment of Gastroenterology, Xuhui Hospital, Zhongshan Hospital of Fudan University, Shanghai, 20031, People's Republic of China.
En-Pan XuEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Qiang ShiEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Shi-Lun CaiEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Di SunEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Li-Qing YaoEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China.
Ping-Hong ZhouEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China. zhou.pinghong@zs-hospital.sh.cn.
Yun-Shi ZhongEndoscopy Center, Zhongshan Hospital of Fudan University, 180 Fenglin Road, Shanghai, 20032, People's Republic of China. zhongyunshi@yahoo.com.ORCID http://orcid.org/0000-0002-3128-3168
Fudan University · CN

Funding

Dawn Program of the Shanghai Education Commission 18SG08Key Technologies Research and Development Program 2018YFC1315000, 2018YFC1315005National Natural Science Foundation of China 81672329, 81861168036National Natural Science Foundation of China 82002515Science and Technology Commission of Shanghai Municipality 19411951600, 19411951601Shanghai Sailing Program 20YF1407200
6 · The paper itself

Abstract

backgroundNOD-like receptors affect multiple stages of cancer progression in many malignancies. NACHT, LRR, and PYD domain-containing protein 7 (NLRP7) is a member of the NOD-like receptor family, although its role in tumorigenesis remains unclear. By analyzing clinical samples, we found that NLRP7 protein levels were upregulated in colorectal cancer (CRC). We proposed the hypothesis that a high level of NLRP7 in CRC may promote tumor progression. Here, we further investigated the role of NLRP7 in CRC and the underlying mechanism.

methodsNLRP7 expression in human CRC and adjacent non-tumorous tissues was examined by quantitative real-time polymerase chain reaction (qRT-PCR), western blotting, and immunohistochemistry. The effect of NLRP7 in CRC progression was investigated in vitro and in vivo. Proteins interacting with NLRP7 were identified by immunoprecipitation and mass spectrometry analysis while immunofluorescence staining revealed the cellular location of the proteins. Cellular ubiquitination and protein stability assays were applied to demonstrate the ubiquitination effect on NLRP7. Cloning and mutagenesis were used to identify a lysine acceptor site that mediates NLRP7 ubiquitination. Cytokines/chemokines affected by NLRP7 were identified by RNA sequencing, qRT-PCR, and enzyme-linked immunosorbent assay. Macrophage phenotypes were determined using qRT-PCR, flow cytometry, and immunohistochemistry.

resultsNLRP7 protein levels, but not mRNA levels, were upregulated in CRC, and increased NLRP7 protein expression was associated with poor survival. NLRP7 promoted tumor cell proliferation and metastasis in vivo and in vitro and interacted with ubiquitin-specific protease 10, which catalyzed its deubiquitination in CRC cells. NLRP7 stability and protein levels in CRC cells were modulated by ubiquitination and deubiquitination, and NLRP7 was involved in the ubiquitin-specific protease 10 promotion of tumor progression and metastasis in CRC. K379 was an important lysine acceptor site that mediates NLRP7 ubiquitination in CRC cells. In CRC, NLRP7 promoted the polarization of pro-tumor M2-like macrophages by inducing the secretion of C-C motif chemokine ligand 2. Furthermore, NLRP7 promoted NF-κB nuclear translocation and activation of C-C motif chemokine ligand 2 transcription.

conclusionsWe showed that NLRP7 promotes CRC progression and revealed an as-yet-unidentified mechanism by which NLRP7 induces the polarization of pro-tumor M2-like macrophages. These results suggest that NLRP7 could serve as a biomarker and novel therapeutic target for the treatment of CRC.

Indexed as

Adaptor Proteins, Signal TransducingAnimalsCell PolarityColorectal NeoplasmsDisease ProgressionFemaleHumansMiceMice, NudeTumor-Associated MacrophagesUbiquitin ThiolesteraseAdaptor Proteins, Signal TransducingNLRP7 protein, humanUbiquitin ThiolesteraseUSP10 protein, humanColorectal cancerDeubiquitinationNLRP7NOD-like receptorsTumor-associated macrophages

Identifiers

PMID33838681
PMCPMC8035766
OpenAlexW3153833944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.